Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-05-22
2007-05-22
Parkin, J. S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
08854825
ABSTRACT:
The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core131-140; SEQ ID NO:1), LLALLSCLTV (Core178-187; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS31169-1177; SEQ ID NO:26), KLVALGINAV (NS31406-1415; SEQ ID NO:28), SLMAFTAAV (NS41789-1797; SEQ ID NO:34), LLFNILGGWV (NS41807-1816; SEQ ID NO:35), and ILDSFDPLV (NS52252-2260; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed.
REFERENCES:
patent: 4565697 (1986-01-01), Ohmura et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4624918 (1986-11-01), Hershberg
patent: 4690915 (1987-09-01), Rosenberg
patent: 4803164 (1989-02-01), Hitzeman et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4977092 (1990-12-01), Bitter
patent: 5017558 (1991-05-01), Vyas
patent: 5019386 (1991-05-01), Machida et al.
patent: 5106726 (1992-04-01), Wang
patent: 5196512 (1993-03-01), Bianchi et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 0 154 902 (1985-09-01), None
patent: 0 291 586 (1988-11-01), None
patent: 0 388 232 (1990-04-01), None
patent: 0 463 848 (1992-02-01), None
patent: WO93/00365 (1993-07-01), None
patent: WO93/18054 (1993-09-01), None
patent: WO 93/18054 (1993-09-01), None
patent: WO 95/12677 (1993-11-01), None
patent: WO93/25575 (1993-12-01), None
patent: WO 95/27733 (1994-04-01), None
patent: 94/20127 (1994-10-01), None
patent: WO 95/22317 (1995-08-01), None
patent: WO-A-95/22317 (1995-08-01), None
Smith et al., 1997, “Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing,” Intl. Immunol. 9(8):1085-1093.
Nayersina et al., 1993, “HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection,” J. Immunol. 150(10):4659-4671.
Bertoletti et al., 1994, “Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope,” J. Exp. Med. 180:933-943.
Johnson et al., 1992, “Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation,” J. Exp. Med. 175:961-971.
Del Val et al., 1991, “Efficient processing of an antigenic sequence for presentation by MCH class I molecules depends on its neighboring residues in the protein,” Cell 66:1145-1153.
Rehermann et al., 1996, “Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection,” J. Clin. Invest. 98(6):1432-1440.
Lewin, R., 1987, “When does homology mean something else?,” Science 237:1570.
Reeck et al., 1987, “Homology” in proteins and nucleic acids: a terminology muddle and a way out of it, Cell 50:667.
Hahn et al., 1992, “CD8+T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope,” J. Exp. Med. 176:1335-1341.
Hansen et al., 1993, “The Major Histocompatibility Complex,” inFundamental Immunology, Paul, ed., Raven Press, New York, NY, pp. 577-628.
Koziel et al., 1993, “Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV,” J. Virol. 67(12):7522-7532.
Monaco, J., 1992, “A molecular model of MHC class-I-restricted antigen processing,” Immunol. Today 13(5):173-179.
Koziel et al., 1997, “Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection,” Springer Semin. Immunopathol. 19:69-83.
Koff, R., 1993, “A redoubtable obstacle to a hepatitis C vaccine,” Gastroenterol. 104(4):1228-1229.
Prince, A., 1994, “Challenges for development of hepatitis C virus vaccines,” FEMS Microbiol. Rev. 14:273-278.
Boswell et al., 1988, “Sequence comparison and alignment: the measurement and interpretation of sequence similarity,” inComputational Molecular Biology: Sources and Methods for Sequence Analysis, Lesk, A., ed., Oxford University Press, New York, pp. 161-178.
Aichele et al., “Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming with a Free Synthetic Peptide,”J. Exp. Med, 171, 1815-1820 (1990).
Allen et al., “Identification of the T-cell and la contact residues of a T-cell antigenic epitope,”Nature 327, 713-715 (1987).
Alter, “Epidemiology of Community-acquired Hepatitis C,”Viral Hepatitis and Liver Disease, pp. 410-413 (Hollinger et al., eds. (1991)).
Bukh et al., “Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay,”Proc. Natl. Acad. Sci. USA, 89, 187-191 (1992).
Carbone et al., “Induction of Cytotoxic T Lymphocytes by Primary In Vivo Stimulation with Peptides,”J. Exp. Med., 167, 1767-1779 (1988).
Cheng et al., “Hepatitis B Virus Large Surface Protein Is Not Secreted but Is Immunogenic when Selectively Expressed by Recombinant Vaccinia Virus,”J. Virol., 60, 334-337 (1986).
Choo et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome,”Science, 244, 334-337 (1989).
Choo et al., “Genetic organization and diversity of the hepatitis C virus,”Proc. Natl. Acad. Sci. USA, 88, 2451-2455 (1991).
Clerici et al., “Detection of Cytotoxic T Lymphocytes Specific for Synthetic Peptides of gp 160 in HIV-Seropositive Individuals,”J. Imm., 146, 2214-2219 (1991).
Deres et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine,”Nature, 342, 561-564 (1989).
Dienstag, “Non-A, Non-B Hepatitis. I. Recognition, Epidemiology, and Clinical Features,”Gastroenterology, 85, 439-462 (1983).
Falk et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,”Nature, 351, 290-296 (1991).
Guo et al., “Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle,”Nature, 360, 364-366 (1992).
Harty et al., “CD8 + T Cells Specific for a Single Nonamer Epitope ofListeria MonocytogenesAre Protective In Vivo,”J. Exp. Med., 175, 1531-1538 (1992).
Houghton et al., “Molecular Biology of the Hepatitis C Viruses: Implications for Diagnosis, Development and Control of Viral Disease,”Hepatology, 14, 381-388 (1991).
Jansen et al., “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,”Immun. Rev., 62, 185-216 (1982).
Jardetzky et al., Identification of self peptides bound to purified HLA-B27,Nature, 353, 326-329 (1991).
Kast et al., “Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide,”Proc. Natl. Acad. Sci. USA, 88, 2283-2287 (1991).
Koziel et al., “Intrahepatic Cytotoxic T Lymphocytes Specific for Hepatitis C Virus in Persons with Chronic Hepatitis,”J. Immunol., 149, 3339-3344 (1992).
Lenzi et al., “Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity,”Lancet, 338, 277-280 (1991).
Maryanski et al., “Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers,”Cell, 60, 63-72 (1990).
Monaco, “A molecular model of MHC class-I-restricted antigen processing,”Immunol. Today, 13
Cerny Andreas
Chisari Francis V.
Parkin J. S.
The Scripps Research Institute
Woodcock & Washburn LLP
LandOfFree
Hepatitis C virus-derived peptides capable of inducing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus-derived peptides capable of inducing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus-derived peptides capable of inducing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784744